• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    LifeMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8/5/25 4:10:43 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care
    Get the next $LFMD alert in real time by email
    false 0000948320 0000948320 2025-08-05 2025-08-05 0000948320 LFMD:CommonStockParValue0.01PerShareMember 2025-08-05 2025-08-05 0000948320 LFMD:Sec8.875SeriesCumulativePerpetualPreferredStockParValue0.0001PerShareMember 2025-08-05 2025-08-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): August 5, 2025

     

    LIFEMD, INC.

    (Exact name of Registrant as specified in its charter)

     

    Delaware   001-39785   76-0238453

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    236 Fifth Avenue, Suite 400

    New York, NY 10001

    (Address of principal executive offices, including zip code)

     

    (866) 351-5907

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

     

    ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.01 per share   LFMD   The Nasdaq Global Market
    8.875% Series A Cumulative Perpetual Preferred Stock, par value $0.0001 per share   LFMDP   The Nasdaq Global Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     
     

     

    Item 2.02. Results of Operations and Financial Condition.

     

    On August 5, 2025, LifeMD, Inc. issued a press release announcing its financial results for the three and six months ended June 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.

     

    The information in this Item 2.02 (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in such filing.

     

    Item 9.01. Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Exhibit
    99.1   Press Release dated August 5, 2025
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        LIFEMD, INC.
           
    Dated: August 5, 2025 By: /s/ Marc Benathen
          Marc Benathen
          Chief Financial Officer

     

     

     

    Get the next $LFMD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LFMD

    DatePrice TargetRatingAnalyst
    6/18/2025$15.00 → $18.00Buy
    BTIG Research
    12/10/2024$12.00Buy
    Lake Street
    12/4/2024$7.00Neutral
    Mizuho
    8/23/2024$11.00Buy
    B. Riley Securities
    6/5/2024$12.00Overweight
    KeyBanc Capital Markets
    11/30/2023$10.00Buy
    Craig Hallum
    7/21/2023$7.00Overweight
    Cantor Fitzgerald
    7/3/2023$9.00Buy
    H.C. Wainwright
    More analyst ratings

    $LFMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Innovation Officer Galluppi Stefan bought $14,790 worth of shares (3,000 units at $4.93), increasing direct ownership by 7% to 45,449 units (SEC Form 4)

    4 - LifeMD, Inc. (0000948320) (Issuer)

    9/12/24 2:10:03 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $LFMD
    SEC Filings

    View All

    SEC Form 10-Q filed by LifeMD Inc.

    10-Q - LifeMD, Inc. (0000948320) (Filer)

    11/17/25 4:52:52 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    LifeMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - LifeMD, Inc. (0000948320) (Filer)

    11/17/25 4:10:58 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    SEC Form NT 10-Q filed by LifeMD Inc.

    NT 10-Q - LifeMD, Inc. (0000948320) (Filer)

    11/12/25 5:16:12 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $LFMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Strawn John R Jr was granted 22,365 shares, increasing direct ownership by 6% to 413,001 units (SEC Form 4)

    4 - LifeMD, Inc. (0000948320) (Issuer)

    10/8/25 6:25:50 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    Director Larovere Joan was granted 22,365 shares, increasing direct ownership by 26% to 107,050 units (SEC Form 4)

    4 - LifeMD, Inc. (0000948320) (Issuer)

    10/8/25 6:03:32 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    Director Ditrolio Joseph was granted 22,365 shares, increasing direct ownership by 9% to 273,413 units (SEC Form 4)

    4 - LifeMD, Inc. (0000948320) (Issuer)

    10/6/25 6:53:00 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $LFMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo Nordisk

    NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services and pharmacy, today announced a new, lower cash-pay price for GLP-1 medications, Wegovy® and Ozempic®, made possible through its ongoing collaboration with Novo Nordisk. LifeMD will now offer the 0.25 mg and 0.5 mg doses at $199 per month—the lowest cash-pay pricing available nationwide—for two fills for new patients. The offering is designed to support patients who pay out of pocket. These medications are available through the LifeMD Weight Management Program, which provides comprehensive support including virtual consultations with LifeMD's dedicated clinical team,

    11/17/25 8:00:55 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    LifeMD to Participate in the BTIG Digital Health Forum

    NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services and pharmacy, today announced its participation in the virtual BTIG Digital Health Forum on November 24, 2025. Management will participate in a virtual panel discussion titled "Creating a Scalable Virtual Primary Care and Obesity Health Platform" at 4:00 p.m. Eastern time and will be available for one-on-one virtual meetings. Investors can register for the conference by contacting their BTIG representative. About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialize

    11/10/25 8:00:00 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    LifeMD Reschedules Third Quarter 2025 Earnings Release and Conference Call to November 17

    NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual healthcare services and pharmacy, today announced that the Company has rescheduled its third quarter 2025 earnings release and conference call to Monday, November 17, 2025. The Company expects to file a Form 12b-25, as needed, notifying the U.S. Securities and Exchange Commission of a late filing of its Form 10-Q for the period ended September 30, 2025. The change to LifeMD's third quarter 2025 earnings release date relates to corrections the Company identified related to the recognition of revenue with offsetting related balance sheet accounts for the twelve months ended December 31, 202

    11/5/25 5:15:00 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $LFMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research reiterated coverage on LifeMD with a new price target

    BTIG Research reiterated coverage of LifeMD with a rating of Buy and set a new price target of $18.00 from $15.00 previously

    6/18/25 10:55:14 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    Lake Street initiated coverage on LifeMD with a new price target

    Lake Street initiated coverage of LifeMD with a rating of Buy and set a new price target of $12.00

    12/10/24 8:29:49 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    Mizuho initiated coverage on LifeMD with a new price target

    Mizuho initiated coverage of LifeMD with a rating of Neutral and set a new price target of $7.00

    12/4/24 7:42:36 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $LFMD
    Leadership Updates

    Live Leadership Updates

    View All

    LifeMD Names COO and Promotes Two Executives

    NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual healthcare services, today announced the appointment of Shayna Webb Dray as its Chief Operating Officer. Ms. Webb Dray, an accomplished operations and supply chain executive with over 15 years of experience, has been an integral part of LifeMD's growth, most recently serving as Senior Vice President of Operations. "Shayna's proven track record of building and managing an industry-leading operations team and infrastructure in a complex and rapidly growing environment makes her the ideal leader to step into the role of COO," said Justin Schreiber, Chairman and Chief Executive Officer of L

    7/31/25 8:00:00 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    LifeMD Set to Join the Russell 3000 Index

    NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective at the open of U.S. equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th. The annual Russell U.S. Indexes reconstitution captures the 4,000 largest U.S. stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Ind

    5/29/24 8:00:00 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    LifeMD Appoints Dr. Calum MacRae to its Board of Directors

    NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the appointment of Calum MacRae, M.D., Ph.D., a clinician, researcher and educator at Harvard Medical School, as an independent member of its Board of Directors. "We are delighted to welcome Dr. MacRae to the LifeMD Board of Directors. He brings deep experience in cardiology, internal medicine and clinical innovation, with a focus on disease management and the implementation of novel solutions to improve the delivery of virtual healthcare services," said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD. "Aside from being a world-reno

    4/29/24 8:00:00 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $LFMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by LifeMD Inc.

    SC 13G/A - LifeMD, Inc. (0000948320) (Subject)

    11/14/24 10:42:44 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G/A filed by LifeMD Inc. (Amendment)

    SC 13G/A - LifeMD, Inc. (0000948320) (Subject)

    2/14/24 3:33:22 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G filed by LifeMD Inc.

    SC 13G - LifeMD, Inc. (0000948320) (Subject)

    10/6/23 5:26:16 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $LFMD
    Financials

    Live finance-specific insights

    View All

    LifeMD Reschedules Third Quarter 2025 Earnings Release and Conference Call to November 17

    NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual healthcare services and pharmacy, today announced that the Company has rescheduled its third quarter 2025 earnings release and conference call to Monday, November 17, 2025. The Company expects to file a Form 12b-25, as needed, notifying the U.S. Securities and Exchange Commission of a late filing of its Form 10-Q for the period ended September 30, 2025. The change to LifeMD's third quarter 2025 earnings release date relates to corrections the Company identified related to the recognition of revenue with offsetting related balance sheet accounts for the twelve months ended December 31, 202

    11/5/25 5:15:00 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    LifeMD to Report Third Quarter 2025 Financial Results on November 6

    NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and nine months ended September 30, 2025 after the close of the U.S. financial markets on November 6, 2025, and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Thursday, November 6thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-245-3047International Dial-In:203-518-9765Conference ID:LIFEMDLive & Archived Webcast:Link   About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and ph

    10/23/25 8:00:00 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

    NEW YORK, Sept. 23, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ:LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on October 15, 2025, to holders of record at the close of business on October 3, 2025. About LifeMD, Inc.LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's

    9/23/25 4:05:00 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care